
AVXL Stock Forecast & Price Target
AVXL Analyst Ratings
Bulls say
Anavex Life Sciences Corp has made significant advancements in its clinical pipeline, particularly with ANAVEX 3-71, which has shown promising Phase 2 results in schizophrenia, indicating a robust platform for treating central nervous system diseases. The company ended fiscal 2025 with approximately $102.6 million in cash, reflecting a modest increase, which positions it well for continued investment in clinical development. Additionally, encouraging efficacy measures and reductions in neuroinflammatory biomarkers suggest potential therapeutic benefits, which, along with a reduced forecasted net loss for fiscal 2026, may enhance investor confidence in the company’s future prospects.
Bears say
Anavex Life Sciences Corp reported a net loss of $0.54 per share, indicating ongoing financial challenges despite a decrease in research and development expenses to $7.3 million from $11.6 million in the prior year, reflecting lower clinical activity. The company faced a significant setback with the recent negative trend vote on the Marketing Authorization Application for its candidate blarcamesine, which reduces the likelihood of gaining crucial regulatory approvals in Europe. Additionally, projections indicate a full-year fiscal 2025 net loss of $0.56 per share, compounded by increased risks associated with clinical data setbacks, potential launch failures, and the dilution risk stemming from ongoing capital needs.
This aggregate rating is based on analysts' research of Anavex Life Sciences and is not a guaranteed prediction by Public.com or investment advice.
AVXL Analyst Forecast & Price Prediction
Start investing in AVXL
Order type
Buy in
Order amount
Est. shares
0 shares